Pfizer

News

Innovent in line for $10.5bn in Pfizer cancer alliance

Pfizer has signed a strategic-level alliance with Innovent, worth $10.5bn and spanning 12 cancer assets, in another sign of China's rising R&D status.

News

Late-breakers to look out for at ASCO 2026

ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.

News

Pfizer takes 25-valent Prevnar follow-up into phase 3

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with new data on a 25-valent candidate.

News

AZ cues up broader use of Imfinzi in bladder cancer

The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

News

Activist investor renews its criticism of Novavax

Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a "destruction in shareholder value."

News

Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss

Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.

Innovent in line for $10.5bn in Pfizer cancer alliance

Late-breakers to look out for at ASCO 2026

Pfizer takes 25-valent Prevnar follow-up into phase 3

AZ cues up broader use of Imfinzi in bladder cancer

Activist investor renews its criticism of Novavax

Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss

Beacon's XLRP gene therapy set for filing after phase 3 win

Discover a new era of healthcare panel engagement: Grounded ...

Pfizer

Editor's Picks